Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Change in Receivables (2022 - 2024)

Opus Genetics (IRD) has disclosed Change in Receivables for 2 consecutive years, with -$9.2 million as the latest value for Q4 2023.

  • On a quarterly basis, Change in Receivables fell 809.24% to -$9.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$372000.0, a 128.66% decrease, with the full-year FY2024 number at $2.6 million, up 808.87% from a year prior.
  • Change in Receivables was -$9.2 million for Q4 2023 at Opus Genetics, down from $10.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $10.0 million in Q3 2023 to a low of -$9.2 million in Q4 2023.